Regeneron Pharmaceuticals Inc (REGN)

The most recent short interest data has been released for the 07/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Stock prices are either unfairly dragged down by competitors' earnings news or by Amazon's spread into more businesses, Cramer said.

Game on: Jim Cramer is bullish on Electronic Arts, Activision Blizzard and Take-Two Interactive.

Case in point: Home Depot and Lowe's.

Jim Cramer says do your homework, be informed and don't let the wise guys trip you up with their warnings about 'single-stock risk.'

Excessive much?

Cramer shares his views on Oracle's re-rating and also discusses the constant battle between growth and value.

The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.

The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.

It just isn't as useful or descriptive right now.

Healthcare leads markets after the release of the Senate health plan.

Healthcare leads markets after the release of the Senate health plan.

Healthcare leads markets after Senate bill's release.

Growth is crushing value, says Jim Cramer, and the dynamic is more pronounced in individual sectors.

Down-and-out stocks have become toxic.

Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea.

Traveling can be a life-changing event, but it's often costly.

We really want to shake out the weak hands here.

Jim Cramer takes a closer look at Inovio Pharmaceuticals, a small biotech developing DNA-based immunotherapies to treat cancer.

Jim Cramer says the story is less about Comey vs. Trump than it is about Nvidia vs. Nordstrom.

Now that's some check.

The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.

Jim Cramer discusses Lululemon and also mentions that the rally is earning some trust.

The market rally broadened out nicely today.

I think the market is obsessing over the Alexion negatives and not looking at the real potential for positive catalysts ahead.

Time to revisit some stocks now that biotech has cooled.

The most recent short interest data has been released for the 04/28/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.